Condition (MeSH)
Antithrombin III Deficiency
ClinicalTrials.gov lists 10 trials for Antithrombin III Deficiency or a narrower condition beneath it. rEVO Biologics has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
10 of the 10 trials are tagged with Antithrombin III Deficiency itself; the rest are tagged with a narrower condition beneath it.
When did Antithrombin III Deficiency trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2021 | 1 |
| 2020 | 1 |
| 2016 | 1 |
| 2015 | 1 |
| 2009 | 1 |
| 2008 | 1 |
| 2005 | 1 |
| 2002 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Antithrombin III Deficiency trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 2/3 | 1 |
| Phase 3 | 3 |
| Phase 4 | 1 |
| Observational | 3 |
How many Antithrombin III Deficiency trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Completed | 4 |
| Terminated | 2 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Antithrombin III Deficiency trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| rEVO Biologics | 2 |
| Instituto Grifols, S.A. | 1 |
| Kyowa Kirin Co., Ltd. | 1 |
| Octapharma | 1 |
| Vastra Gotaland Region | 1 |
Which drugs are being tested for Antithrombin III Deficiency? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Antithrombin III | 3 |
| KW-3357 | 1 |
Interventions as named in the registry (3)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Recombinant Human Antithrombin (rhAT) | 2 |
| Human plasma derived antithrombin | 1 |
| Plasma-derived AT-III concentrate | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Antithrombin III Deficiency trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cellulitis | 1 | 1 |
| Convulsions Grand Mal | 1 | 1 |
| DVT | 1 | 1 |
| Enterobacter Sepsis | 1 | 1 |
| Fever | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Antithrombin III Deficiency? (12)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Acquired antithrombin deficiency in adult patients with postcardiotomy extracorporeal membrane oxygenation. | Perfusion | 2025 | Yes |
| Antithrombin: anti-inflammatory properties and clinical applications. | Thrombosis and haemostasis | 2016 | Yes |
| Antithrombin III/SerpinC1 insufficiency exacerbates renal ischemia/reperfusion injury. | Kidney international | 2015 | Yes |
| Pharmacokinetics of recombinant human antithrombin in delivery and surgery patients with hereditary antithrombin deficiency. | Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis | 2014 | Yes |
| Mild antithrombin deficiency and risk of recurrent venous thromboembolism: a prospective cohort study. | Circulation | 2014 | Yes |
Showing 5 of 12 publications.
Prevalence (1)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Hereditary thrombophilia due to congenital antithrombin deficiency | Point prevalence | 1-5 / 10 000 | Worldwide | Not stated | Unspecified |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: rare-disease identity and sub-conditions in mesh.